D-dimer antigen: Current concepts and future prospects

Blood

Volumn 113, Issue 13, 2009, Pages 2878-2887

  Adam, Soheir S ^a,c   Key, Nigel S ^a   Greenberg, Charles S ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c University of North California at Chappel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13A; CYTOTOXIC AGENT; D DIMER; FIBRIN; FIBRINOGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HEPARIN; IMMUNOMODULATING AGENT; LOW MOLECULAR WEIGHT HEPARIN; MONOMER; PLASMIN; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; THALIDOMIDE; THROMBIN;

ACUTE DISEASE; ANEMIA; ANTICOAGULATION; ANTIGEN DETECTION; AORTA DISSECTION; BLOOD CLOTTING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CATALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOKINE RELEASE SYNDROME; CYTOPENIA; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG INDUCED DISEASE; FIBRIN CLOT; FIBRINOLYSIS; HEMOLYSIS; HEPARINIZATION; HUMAN; HYPERTENSION; HYPERVISCOSITY SYNDROME; IMMUNOASSAY; INTERMETHOD COMPARISON; LABORATORY TEST; LUNG CANCER; LUNG EMBOLISM; NEOPLASM; PREGNANCY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN POLYMERIZATION; PROTEIN SECRETION; RECURRENT DISEASE; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; STEM CELL TRANSPLANTATION; THALASSEMIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 63849275090     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-165845     Document Type: Review

References (117)

1. Blomback B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature. 1978;275:501-505.
2. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3:1894- 1904.
3. Laudano AP, Doolittle RF. Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc Natl Acad Sci U S A 1978;75:3085-3089.
4. Fowler WE, Erickson HP, Hantgan RR, McDonagh J, Hermans J. Cross-linked fibrinogen dimers demonstrate a feature of the molecular packing in fibrin fibers. Science. 1981;211:287-289.
5. Doolittle RF, Pandi L. Probing the beta-chain hole of fibrinogen with synthetic peptides that differ at their amino termini. Biochemistry. 2007;46: 10033-10038.
6. Greenberg CS, Miraglia CC, Rickles FR, Shuman MA. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting. J Clin Invest. 1985;75:1463-1470.
7. Greenberg CS, Achyuthan KE, Rajagopalan S, Pizzo SV. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII. Arch Biochem Biophys. 1988; 262:142-148.
8. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin- independent inhibitors. Circulation. 1998;97:544-552.
9. Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem. 1996;271:23121-23125.
10. Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest. 1983;71:1336-1341.
11. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost. 2003;89:409-419.
12. Gaffney PJ. Distinction between fibrinogen and fibrin degradation products in plasma. Clin Chim Acta. 1975;65:109-115.
13. Lane DA, Preston FE, VanRoss ME, Kakkar VV. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation. Br J Haematol. 1978;40: 609-615.
14. Gaffney PJ. Fibrin degradation products. A review of structures found in vitro and in vivo. Ann N Y Acad Sci. 2001;936:594-610.
15. Marder VJ, Zareba W, Horan JT, Moss AJ, Kanouse JJ. Automated latex agglutination and ELISA testing yield equivalent D-dimer results in patients with recent myocardial infarction. THROMBO Research Investigators. Thromb Haemost. 1999;82:1412-1416.
16. Kornberg A, Francis CW, Marder VJ. Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D- dimer and measurement in normal and patients with acute thrombotic disorders. Blood. 1992;80: 709-717.
17. Dempfle CE. Validation, calibration, and specificity of quantitative D-dimer assays. Semin Vasc Med. 2005;5:315-320.
18. Gaffney PJ, Edgell T, Creighton-Kempsford LJ, Wheeler S, Tarelli E. Fibrin degradation product (FnDP) assays: analysis of standardization issues and target antigens in plasma. Br J Haematol. 1995;90:187-194.
19. Gaffney PJ, Lane DA, Kakkar VV, Brasher M. Characterisation of a soluble D dimer-E complex in crosslinked fibrin digests. Thromb Res. 1975;7: 89-99.
20. Gaffney PJ, Joe F. The lysis of crosslinked human fibrin by plasmin yields initially a single molecular complex, D dimer-E. Thromb Res. 1979;15:673-687.
21. Francis CW, Marder VJ, Barlow GH. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure. J Clin Invest. 1980;66:1033-1043.
22. Rylatt DB, Blake AS, Cottis LE, et al. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res. 1983;31:767-778.
23. Greenberg CS, Devine DV, McCrae KM. Measurement of plasma fibrin D-dimer levels with the use of a monoclonal antibody coupled to latex beads. Am J Clin Pathol. 1987;87:94-100.
24. Dempfle CE, Zips S, Ergul H, et al. The Fibrin Assay Comparison Trial (FACT): evaluation of 23 quantitative D-dimer assays as basis for the development of D-dimer calibrators. FACT study group. Thromb Haemost. 2001;85:671-678.
25. Meijer P, Haverkate F, Kluft C, de Moerloose P, Verbruggen B, Spannagl M. A model for the harmonisation of test results of different quantitative D-dimer methods. Thromb Haemost. 2006;95:567-572.
26. Devine DV, Greenberg CS. Monoclonal antibody to fibrin D-dimer (DD-3B6) recognizes an epitope on the gamma-chain of fragment D. Am J Clin Pathol. 1988;89:663-666.
27. Elms MJ, Bunce IH, Bundesen PG, et al. Rapid detection of cross-linked fibrin degradation products in plasma using monoclonal antibody-coated latex particles. Am J Clin Pathol. 1986;85:360- 364.
28. Mountain D, Jacobs I, Haig A. The VIDAS D-dimer test for venous thromboembolism: a prospective surveillance study shows maintenance of sensitivity and specificity when used in normal clinical practice. Am J Emerg Med. 2007;25:464-471.
29. Lippi G, Salvagno GL, Rossi L, Montagnana M, Franchini M, Guidi GC. Analytical performances of the D-dimer assay for the Immulite 2000 automated immunoassay analyser. Int J Lab Hematol. 2007;29:415-420.
30. Froehling DA, Daniels PR, Swensen SJ, et al. Evaluation of a quantitative D-dimer latex immu- noassay for acute pulmonary embolism diagnosed by computed tomographic angiography. Mayo Clin Proc. 2007;82:556-560.
31. Dempfle CE. D-dimer: standardization versus harmonization. Thromb Haemost. 2006;95:399-400.
32. Perrier A. Review: The Wells clinical prediction guide and D-dimer testing predict deep vein thrombosis. Evid Based Med. 2006;11:119.
33. Kruip MJ, Slob MJ, Schijen JH, van der Heul C, Buller HR. Use of a clinical decision rule in combination with D-dimer concentration in diagnostic workup of patients with suspected pulmonary embolism: a prospective management study. Arch Intern Med. 2002;162:1631-1635.
34. Pittet JL, de Moerloose P, Reber G, et al. VIDAS D-dimer: fast quantitative ELISA for measuring D-dimer in plasma. Clin Chem. 1996;42:410-415.
35. Scarano L, Bernardi E, Prandoni P, et al. Accuracy of two newly described D-dimer tests in patients with suspected deep venous thrombosis. Thromb Res. 1997;86:93-99.
36. Dale S, Gogstad GO, Brosstad F, et al. Comparison of three D-dimer assays for the diagnosis of DVT:ELISA, latex and an immunofiltration assay (NycoCard D-Dimer). Thromb Haemost. 1994;71: 270-274.
37. Curtin N, Highe G, Harris M, Braunstein A, Demattia F, Coss L. Extensive evaluation of the instrumentation laboratory IL test D-Dimer immunoturbidimetric assay on the ACL 9000 determines the D-Dimer cutoff value for reliable exclusion of venous thromboembolism. Lab Hematol. 2004;10:88-94.
38. John MA, Elms MJ, O'Reilly EJ, Rylatt DB, Bundesen PG, Hillyard CJ. The simpliRED D dimer test: a novel assay for the detection of crosslinked fibrin degradation products in whole blood. Thromb Res. 1990;58:273-281.
39. de Groot MR, van Marwijk Kooy M, Pouwels JG, Engelage AH, Kuipers BF, Buller HR. The use of a rapid D-dimer blood test in the diagnostic work-up for pulmonary embolism: a management study. Thromb Haemost. 1999;82:1588-1592.
40. Di Nisio M, Squizzato A, Rutjes AW, Buller HR, Zwinderman AH, Bossuyt PM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost. 2007;5:296-304.
41. Lowe GD. Fibrin D-dimer and cardiovascular risk. Semin Vasc Med. 2005;5:387-398.
42. Rathbun SW, Whitsett TL, Vesely SK, Raskob GE. Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest. 2004; 125:851-855.
43. Wells PS. Integrated strategies for the diagnosis of venous thromboembolism. J Thromb Haemost. 2007;5:41-50.
44. Elms MJ, Bunce IH, Bundesen PG, et al. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies. Thromb Haemost. 1983;50:591-594.
45. Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med. 2004;140:589-602.
46. Arnason T, Wells PS, Forster AJ. Appropriateness of diagnostic strategies for evaluating suspected venous thromboembolism. Thromb Haemost. 2007;97:195-201.
47. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83:416-420.
48. Gibson NS, Sohne M, Kruip MJ, et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost. 2008;99:229-234.
49. Linkins LA. Reproducibility of pretest assessment in suspected pulmonary embolism. Lab Med. 2008;39:361-364.
50. Stein PD, Beemath A, Olson RE. Trends in the incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients. Am J Cardiol. 2005;95:1525-1526.
51. Brotman DJ, Segal JB, Jani JT, Petty BG, Kickler TS. Limitations of D-dimer testing in unselected inpatients with suspected venous thromboembolism. Am J Med. 2003;114:276-282.
52. Meesters EW, Hansen H, Spronk HM, et al. The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagul Fibrinolysis. 2007;18:21-28.
53. Brenner B, Francis CW, Totterman S, et al. Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. Circulation. 1990;81:1818-1825.
54. IbaT, GandoS, Murata A, et al. Predicting the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with he- mostatic molecular markers and vascular endothelial injury markers. J Trauma. 2007;63:1093-1098.
55. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med. 2003;114:180-187.
56. Harper PL, Theakston E, Ahmed J, Ockelford P. D-dimer concentration increases with age reducing the clinical value of the D-dimer assay in the elderly. Intern Med J. 2007;37:607-613.
57. Legnani C, Palareti G, Cosmi B, et al. Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. Haematologica. 2008;93:900-907.
58. Couturaud F, Kearon C, Bates SM, Ginsberg JS. Decrease in sensitivity of D-dimer for acute venous thromboembolism after starting anticoagulant therapy. Blood Coagul Fibrinolysis. 2002;13: 241-246.
59. Ranji SR, Shojania KG, Trowbridge RL, Auerbach AD. Impact of reliance on CT pulmonary angiog- raphy on diagnosis of pulmonary embolism: a Bayesian analysis. J Hosp Med. 2006;1:81-87.
60. van Belle A, Buller HR, Huisman MV, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA. 2006;295:172-179.
61. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and D-dimer. Ann Intern Med. 2001;135:98-107.
62. Söderberg M, Brohult J, Jorfeldt L, Lärfars G. The use of D-dimer testing and Wells score in patients with high probability for acute pulmonary embolism. J Eval Clin Pract. 2009;15:129-133.
63. Douma RA, Kamphuisen PW, Huisman MV, Buller HR. False normal results on multidetector- row spiral computed tomography in patients with high clinical probability of pulmonary embolism. J Thromb Haemost. 2008;6:1978-1979.
64. Stein PD, Fowler SE, Goodman LR, et al. Multidetec- tor computed tomography for acute pulmonary embolism. N Engl J Med. 2006;354:2317-2327.
65. Galle C, Papazyan JP, Miron MJ, Slosman D, Bounameaux H, Perrier A. Prediction of pulmonary embolism extent by clinical findings, D-dimer level and deep vein thrombosis shown by ultrasound. Thromb Haemost. 2001;86:1156-1160.
66. Tick LW, Nijkeuter M, Kramer MH, et al. High D- dimer levels increase the likelihood of pulmonary embolism. J Int Med. 2008;264:195-200.
67. Schutgens RE, Esseboom EU, Snijder RJ, et al. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. J Lab Clin Med. 2004;144:100-107.
68. Bates S, Kearon C, Kahn S, et al. A negative D- dimer excludes recurrent deep vein thrombosis: results of a multicentre management study [abstract]. Blood. 2007;110:698.
69. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780-1789.
70. Lee AY, Julian JA, Levine MN, et al. Clinical utility of a rapid whole-blood D-dimer assayin patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med. 1999; 131:417-423.
71. Carrier M, Lee AY, Bates SM, Anderson DR, Wells PS. Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thromb Res. 2008;123:177-183.
72. Righini M, Le Gal G, De Lucia S, et al. Clinical usefulness of D-dimer testing in cancer patients with suspected pulmonary embolism. Thromb Haemost. 2006;95:715-719.
73. King V, Vaze AA, Moskowitz CS, Smith LJ, Ginsberg MS. D-Dimer assay to exclude pulmonary embolism in high-risk oncologic population: correlation with CT pulmonary angiography in an urgent care setting. Radiology. 2008;247:854-861.
74. Eichinger S. D-dimer testing in pregnancy. Semin Vasc Med. 2005;5:375-378.
75. Chan W-S, Chunilal S, Lee A, Crowther M, Rodger M, Ginsberg JS. A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med. 2007; 147:165-170.
76. Stein PD, Woodard PK, Weg JG, et al. Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II investigators. Am J Med. 2006;119:1048-1055.
77. Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-1330.
78. Wada H, Gabazza EC, Asakura H, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol. 2003;74:17-22.
79. Hayakawa M, Gando S, Hoshino H. A Prospective comparison of new Japanese criteria for disseminated intravascular coagulation: new Japanese criteria versus ISTH criteria. Clin Appl Thromb Hemost. 2007;13:172-181.
80. Voves C, Wuillemin WA, Zeerleder S. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis. 2006; 17:445-451.
81. Dempfle CE. Disseminated intravascular coagulation and coagulation disorders. Curr Opin An- aesthesiol. 2004;17:125-129.
82. Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost. 1999;82:673-683.
83. Sodeck G, Domanovits H, Schillinger M, et al. D-Dimer in ruling out acute aortic dissection: a systematic review and prospective cohort study. Eur Heart J. 2007;28:3067-75.
84. Nadir Y, Hoffman R, Brenner B. Drug-related thrombosis in hematologic malignancies. Rev Clin Exp Hematol. 2004;8:E4.
85. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381-388.
86. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-924.
87. Shibata J, Hasegawa J, Siemens HJ, et al. He- mostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis. Blood. 2003;101:4416-4422.
88. Christensson AG, Danielson BG, Lethagen SR. Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis. Nephrol Dial Transplant. 2001;16:313-319.
89. Canales MA, Arrieta R, Gomez-Rioja R, Diez J, Jimenez-Yuste V, Hernandez-Navarro F. Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors. J He- matother Stem Cell Res. 2002;11:675-681.
90. Topcuoglu P, Arat M, Dalva K, Ozcan M. Administration of granulocyte-colony-stimulating factor for allo- geneic hematopoietic cell collection mayinduce the tissue factor-dependentpathwayin healthydonors. Bone Marrow Transplant. 2004;33:171-176.
91. Stephens LC, Haire WD, Schmit-PokornyK, Kessinger A, Kotulak G. Granulocyte macro- phage colony stimulating factor: high incidence of apheresis catheter thrombosis during peripheral stem cell collection. Bone Marrow Transplant. 1993;11:51-54.
92. Galimberti R, Pietropaolo N, Galimberti G, Kowalczuk A. Adult purpura fulminans associated with staphylococcal infection and administration of colony-stimulating factors. Eur J Dermatol. 2003;13:95-97.
93. Cappellini MD. Coagulation in the pathophysiology of hemolytic anemias. HematologyAm Soc Hematol Educ Program. 2007;2007:74-78.
94. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program. 2007;2007:91-96.
95. Stuart MJ, Setty BN. Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med. 2001;20:27-46.
96. Austin H, Key NS, Benson JM, et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood. 2007;110:908-912.
97. Ittyerah R, Alkjaersig N, Fletcher A, Chaplin H. Coagulation factor XIII concentration in sickle-cell disease. J Lab Clin Med. 1976;88:546-554.
98. Francis RB Jr. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis. 1989;19:105-111.
99. Mohan JS, Lip GY, Wright J, Bareford D, Blann AD. Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation. Blood Coagul Fibrinolysis. 2005;16:209-214.
100. Gillis S, Cappellini MD, Goldfarb A, Ciceri L, Fiorelli G, Rachmilewitz EA. Pulmonary thromboembolism in thalassemia intermediapatients. Haematologica. 1999;84:959-960.
101. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemiaintermedia. Br J Haematol. 2000;111:467-473.
102. Tripatara A, Jetsrisuparb A, Teeratakulpisarn J, Kuaha K. Hemostatic alterations in splenectomized and non-splenectomized patients with [beta]-thalassemia/hemoglobin E disease. Thromb Res. 2007;120:805-810.
103. Streetly M, Hunt BJ, Parmar K, Jones R, Zeldis J, Schey S. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatoryagentActimid™(CC- 4047) and their relationship with venous thrombosis. Eur J Haematol. 2005;74:293-296.
104. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118:555-568.
105. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217-2224.
106. Weitz IC, Israel VK, Waisman JR, Presant CA, Rochanda L, Liebman HA. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost. 2002;88:213-220.
107. Matsumoto T, Wada H, Nishiyama H, et al. Hemostatic abnormalities and changes following bone marrow transplantation. Clin Appl Thromb Hemost. 2004;10:341-350.
108. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-Dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349: 1227-1235.
109. Indik JH, Alpert JS. Detection of pulmonaryem- bolism by D-dimer assay, spiral computed tomography, and magnetic resonance imaging. Prog Cardiovasc Dis. 2000;42:261-272.
110. BounameauxH. Review: ELISA D-dimer is sensitive but not specific in diagnosing pulmonary embolism in an ambulatory clinical setting. ACP J Club. 2003;138:24.
111. Fukuda T, Kasai H, Kusano T, Shimazu C, Kawasugi K, Miyazawa Y. A rapid and quantitative D-Dimer assay in whole blood and plasma on the point-of-care PATHFAST analyzer. Thromb Res. 2007;120:695-701.
112. Dempfle CE, Suvajac N, Elmas E, Borggrefe M. Performance evaluation of a new rapid quantitative assay system for measurement of D-dimer in plasma and whole blood: PATHFAST D-dimer. Thromb Res. 2007;120:591-596.
113. Killick SB, Pentek PG, Mercieca JE, Clarke MF, Bevan DH. Comparison of immunofiltration assay of plasma D-dimer with diagnostic imaging in deep vein thrombosis. Br J Haematol. 1997;96:846-849.
114. Veitl M, Hamwi A, Kurtaran A, Virgolini I, Vukovich T. Comparison of four rapid D-Dimer tests for diagnosis of pulmonary embolism. Thromb Res. 1996;82:399-407.
115. Sukhu K, Beavis J, Baker PM, Keeling DM. Comparison of an immuno-turbidometric method (STalia D-DI) with an established enzyme linked fluorescent assay (VIDAS) D-dimer for the exclusion of venous thromboembolism. Int J Lab Hematol. 2008;30:200-204.
116. Toulon P, Lecourvoisier C, Meyniard O. Evaluation of a rapid qualitative immuno-chromatogra- phy D-dimer assay (Simplify D-dimer) for the exclusion of pulmonary embolism in symptomatic outpatients with a low and intermediate pretest probability. Comparison with two automated quantitative assays. Thromb Res. 2009;123:543-549.
117. Righini M, Perrier A, de Moerloose P, Bounameaux H. D-dimer for venous thromboembolism diagnosis: twenty years later. J Thromb Haemost. 2008;6:1059-1071.